Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · TG Therapeutics (TGTX)

TG Therapeutics raises 2024 BRIUMVI revenue guidance to $300 million-$305 million

Mixed Impact 4 of 5 guidance Written later

TG Therapeutics reported third quarter 2024 results and raised its full-year 2024 U.S. BRIUMVI net product revenue target to $300 million to $305 million, up from $290 million to $300 million. Product sales are growing quickly, but total revenue and net income fell sharply from the prior-year period, which included a large license payment.

Key points

  • Q3 2024 U.S. BRIUMVI net product revenue was $83.3 million, about 15% above the prior quarter and over 230% above Q3 2023.
  • Full-year 2024 U.S. BRIUMVI net revenue target raised to $300 million to $305 million from $290 million to $300 million.
  • Q3 2024 net income was $3.9 million, compared with $113.9 million in Q3 2023, which included license revenue of $140.7 million.
  • Cash, cash equivalents and investment securities were $341.0 million as of September 30, 2024.

The filing

CompanyTG Therapeutics (TGTX)
Form8-K, current report
Filed with the SECNov 4, 2024, 7:19 AM ET
Accession number0001437749-24-033055

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.